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ABSTRACT
OBJECTIVE: The objective of this EBM review is to determine whether or not Apixaban is effective 
for the prevention of stroke in patients with non-valvular atrial fibrillation.
STUDY DESIGN: Review of three English language primary studies published all published in 2011.
DATA SOUCRES: Three double-blind randomized control trials found using the Cochrane Database 
and PubMed.
OUTCOME(S) MEASURED:  Outcomes measured were occurrence of stroke (TIA or CVA), systemic 
embolism, major bleeding or clinically relevant non-major bleeding, and incidence of death.
RESULTS: Apixaban 2.5mg and 5mg were both superior to Warfarin in the prevention of stroke or 
systolic embolism and also decreased the rate of intracranial hemorrhage or other clinically relevant 
bleeding. Apixaban 5mg was also demonstrated superiority compared to aspirin 81-324mg in reduction 
of stroke, systemic embolism, and death rates.
CONCLUSION: In patients with atrial fibrillation, apixaban was superior to both warfarin (adjusted to 
an INR 2.0-3.0) and aspirin (81-324mg) in the indication of prevention of stroke or systemic embolism.
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INTRODUCTION
Atrial fibrillation is the most common chronic arrhythmia with an incidence and prevalence that
increases with age. Atrial fibrillation can occur in conjunction with other diseases  that affect the 
function of the heart such as rheumatic heart disease, many forms of valvular heart disease, dilated 
cardiomyopathy, atrial septal defect, coronary heart disease and can also present in patients without any
prior history of cardiac disease 5. The mechanism of cause is still debatable. Current theories involve 
complex interaction between the initiation and the musculature in the atria that responds to this 
impulse. 
Symptoms of atrial fibrillation include: irregular heartbeat, tachycardia, lightheartedness, 
extreme fatigue, shortness of breath with chest pain. This condition is routinely diagnosed by ECG 
interpretation due to its disorganized atrial activity and irregular ventricular response.  Episodes of 
atrial fibrillation can be classified as paroxysmal (hours to days), persistent (lasts for days and is 
corrected with intervention), or permanent 5. Atrial fibrillation reduces the amount of blood that is 
pumped from the atria into the ventricles increasing the chance dangerous clot formation which can go 
on to embolize and cause infarction. Due to the potential for emboli to reach the brain atrial fibrillation 
is known to be the cause of 15-20% of ischemic strokes 5. The focus of this study will be patients that 
have non-valvular atrial fibrillation, defined as being in of rheumatic heart disease, a prosthetic heart 
valve or previous valve repair.
Atrial fibrillation, in general, is relatively common with an estimated 2.66 million people 
having been diagnosed with this disorder in 2010. The average age of a patient with atrial fibrillation is 
67 for men and 75 for women 4. Demographics wise atrial fibrillation is also more prevalent in white 
than black populations. Occurring to the CDC the estimated cost of treatment for atrial fibrillation was 
$6.65 billion per year; this figure includes cost of hospitalization, in/outpatient physician care and 
medications 4. Though there is not an exact estimate of how many healthcare visits are due to atrial 
fibrillation complications it is projected that 12 million people will have this condition by 2050. In 
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addition the mortality rate from atrial fibrillation either as a primary or an underlying cause of death 
has been increasing for more than two decades 4. 
There are multiple methods in which non-valvular atrial fibrillation is treated. Treatment is 
initiated through the use of medication to control rate and rhythm (amiodarone, verapamil, diltiazem) 
and surgical ablation therapy. The gold standard anticoagulant prophylaxis for emboli from potential 
clot formation is warfarin, but other anticoagulant therapeutic agents such as IV heparin and oral 
aspirin have also been successful in the prevention of stroke and other thromboembolic events 5. 
Warfarin is recommended for patients with a INRs (international normalized ratio) in between 2.0-3.0 
with increased risk for stroke/thromboembolic events. These risks include previous stroke, TIA, 
systemic emboli, previous symptomatic heart failure or left ventricular ejection <40%, diabetes, and/or 
hypertension3..
Factor Xa inhibitors are another classification of anticoagulants which directly target the 
clotting factor Xa to prevent clot formation.  Traditionally these  agents have been used in place of 
warfarin or LMWH to prevent venous thrombosis after hip or knee replacement surgery. Unlike 
warfarin these agents have no required need for coagulation monitoring. In 2012 Apixaban, a factor Xa 
inhibitor was approved for the prevention of stroke in patients with non-valvular atrial fibrillation after 
exploration of the medications efficacy with studies of this patient population.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is apixaban  
effective for the prevention of stroke in patients with non-valvular atrial fibrillation”.
METHODS 
The studies in this selective Evidence Based Medicine review included men and women 
diagnosed with atrial fibrillation. The inclusion criteria were based on the following risk factors: ages 
greater than or equal to 75yrs, history of previous stroke (TIA or cerebral infraction), history systemic 
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embolism, CHF (left ventricular ejections fraction of less than or equal to 40%), hypertension requiring
pharmacological treatment, or a diagnosis of diabetes mellitus. Exclusion criteria included atrial 
fibrillation due to a reversible cause, moderate or severe mitral stenosis, stroke within the previous 
seven days, severe renal insufficiency (serum creatinine level of >2.5mg or CrCl of <25ml/min) 1,2,3. 
The intervention addressed was Apixaban 2.5mg or 5mg BID compared against Warfarin titrated to an 
INR level between 2.0-3.0 and aspirin dosed 81-324mg given once a daily. Outcomes were measured in
the occurrence of stroke and/or systemic embolism, MI, major bleeding, clinically relevant non-major 
(CRNM) bleeding or death. These three studies compared are double-blind randomized controlled trials
using apixaban, compared with warfarin, aspirin or both. In all three of the studies detailed in this 
review CHADS2 scale was used to measure a patients risk of stroke.
Data sources included both Cochrane and Pubmed databases using the keywords “Atrial 
fibrillation”, “apixaban”, “stroke”,  “warfarin”, and “prevention” between 2003-2013. All articles were 
published in English in 2011 and were selected based on relevance to patients with atrial fibrillation. 
Statistics include p-value, RRR, ARR and NNT. Articles were selected based on their relevance to my 
clinical question and if they included POEMs.
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Table 1: Demographics & Characteristics of included studies
Study Type #pts Age
(yrs)
Inclusion Criteria Exclusion
Criteria
W/D Interventions
Joyner et al1 
(2011)
Double-
blind 
RCT
18201 50 or 
older
Men  or women aged 50 years 
or older with documented 
atrial fibrillation that have one 
or more of the following risk 
factors for stroke:
-Age greater than or equal to 
75yrs
Previous stroke, TIA or 
systemic embolism
-CHF (left ventricular ejection 
fraction of less than or equal to
35%)
-Documented peripheral artery
disease
-HTN requiring 
pharmacologic treatment 
-DM
-Could not be receiving 
vitamin K antagonist therapy 
because it was previously 
proven to be unsuitable for 
them or it was expected to be 
unsuitable
Presence  of conditions 
other than atrial 
fibrillation for which the 
patient  required long-
term anticoagulation, 
Valvular disease 
requiring surgery
Serious bleeding event in
the previous 6 months  or
a high risk of bleeding 
( active peptic ulcer 
disease, platelet count 
under 100,000, 
hemoglobin level of 
<10g/dl, stroke within 
the past 10 days, 
documented hemorrhagic
tendenices, or blood 
dyscrasias)
Current alcohol or drug 
abuse/psychosocial 
issues
None (early
termination 
of the 
study)
Apixaban 5mg
1 tab PO BID
Ogawa, 
Shinohara, 
and 
Kanmuri2
(2011)
Double-
blind 
RCT
222 20 or 
older
Men  or women with 
documented atrial fibrillation 
that have one or more of the 
following risk factors for 
stroke:
Age greater than or equal to 
75yrs
CHF (left ventricular ejection 
fraction of less than or equal to
40%)
HTN requiring medication
DM
History of cerebral infraction 
or TIA
Recent cerebral 
infraction (including 
TIA)
Valvular heart disease
Sick sinus syndrome or 
severe conduction 
disturbance
Non-cardiogenic stroke 
requiring aspirin or 
aspirin and anti-platelet 
agents
Contraindications for 
warfarin use
Severe or refractory HTN
Current 
thrombocytopenia 
(platelet count under 
100x109 /L or 
hemoglobin less than 
10g/dl)
Renal dysfunction 
(creatinine clearance  < 
25ml/min)
LFT abnormalities (ALTs
or AFTs greater than or 
equal to 2x the upper 
limit of normal)
0 Apixaban 
2.5mg or 5mg 
1tab po BID
Granger, 
Alexandar, 
McMurray et
al.3 (2011)
Double-
blind
RCT
5599 50 or 
older
Men  or women with 
documented atrial 
fibrillation that have 
one or more of the 
following risk factors 
for stroke:
Age greater than or 
equal to 75yrs
Previous stroke, TIA or 
systemic embolism
CHF (left ventricular 
ejection fraction of less 
than or equal to 40%)
HTN requiring 
pharmacologic 
treatment 
DM
Atrial fibrillation due 
to a reversible cause 
Moderate or severe 
mitral stenosis
Conditions other than 
atrial fibrillation that 
required 
anticogulation
Stroke with the 
previous 7 days 
Need for aspirin at a 
dose >165mg qd or 
for both aspirin and 
clopidogrel
Severe renal 
insufficiency (serum 
creatinine level of  
>2.5mg/dl or 
calculated creatinine 
clearance of 
<25ml/min)
N/A Apixaban 5mg
1 tab po BID
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OUTCOMES
All outcomes were measured in relation to the incidence of stroke or other thromboembolic 
event during the time that patients were using the treatment medication (apixaban, warfarin, or aspirin).
Favorable outcomes included a decrease in the rate of stroke or systemic embolism, intracranial 
bleeding, myocardial infarction or pulmonary embolism. Unfavorable outcomes included an increase in
the rate of death, stroke, systemic embolism, clinically relevant major or non major bleeds, myocardial 
infarction, or death.
Stroke was defined as a focal neurologic deficit, originating from a non-traumatic cause, lasting 
for at least 24 hours and was categorized as ischemic or hemorrhagic from evaluation of brain imaging 
studies (MRI, CT without contract). Those in whom imaging or an autopsy was not performed were 
classified as “uncertain” 3. Systemic embolism was defined as an acute vascular occlusion of an 
extremity or organ. Major bleeding was defined as an acute, clinically overt, and with 1 or more of the 
following: decrease in hemoglobin >2g/dl over a 24hr period; bleeding  requiring a  transfusion of >2 
units of packed red blood cells, or bleeding at the critical site (intracranial, intraspinal, intraocular, 
intra-articular), or bleeding that was fatal 2. Clinically relevant non-major bleeding was defined as acute
or subacute, clinically overt, not major that lead to hospital admission or physical guided medical or 
surgical treatment 2.
In the study comparing Apixaban and Warfarin in Patients with Atrial Fibrillation apixaban was 
administered at a dose of 5mg twice a day or Warfarin titrated to an INR 2.0-3.0. Those participants 
that were on previously initiated warfarin therapy were asked to discontinue their medication  three 
days before randomization. The primary outcome was ischemic or hemorrhagic stroke or systemic 
embolism. This trial was designed to test for non-inferiority with a secondary objectives of testing for 
superiority.
In the study comparing the Safety and Efficacy of Oral Direct Factor Xa Inhibitor Apixaban in 
Japanese Patients with Non-Valvular Atrial Fibrillation apixaban was given in either doses of 2.5mg or 
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5mg twice a day or open-label warfarin titrated to an INR of 2.0-3.0 for 12 weeks. The endpoint being 
occurrence of major and clinically relevant non-major bleeding. 
In the study Apixaban in Patients with Atrial Fibrillation this patient population consisted of 
those whom Vitamin K antagonist therapy was unsuitable. Apixaban was dosed at 5mg twice daily and 
aspirin was compared to aspirin dosed 81-324mg daily. The primary outcome was occurrence of stroke 
or systemic embolism. This trial was designed to test for superiority of apixaban when compared with 
aspirin.
RESULTS
In the study Apixaban and Warfarin in Patients with Atrial Fibrillation the rate of the primary 
outcome (stroke or systemic embolism) were compared with patients given apixaban 5mg and those 
given Warfarin adjusted to an INR of 2.0-3.0. Rates of stroke or systemic embolism in the apixaban 
group were decreased when compared to warfarin (Hazard ratio =0.79; 95% CI, 0.66-0.95; P<0.01;). 
With a primary outcome event ratio of apixaban and warfarin 1.27% and 1.60% per year, respectively. 
Incidence of major bleeding also decreased in the apixaban group compared to the warfarin group 
(Hazard ratio =0.69, 95% CI 0.60-0.80, P<0.001). The yearly event rate of major bleeding in the 
apixaban and warfarin groups were 2.13% and 3.09%. In addition the net clinical outcomes  (stroke, 
systemic embolism, major bleeding, or death from any cause) were lower in the apixaban group than 
the warfarin group (Hazard ratio = 0.85, 95% CI 0.78-0.92, P<0.001); with event rates 6.13% and 
7.20% respectively. When evaluating the treatment effect of apixaban 5mg versus warfarin the RRR 
was 20%, ARR was 0.33% and the NNT was 303.
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Table 2: Rates of Primary and Secondary Event Outcomes in Granger et al 2011
Event Rate (%) Apixaban 
(5mg)
Warfarin 
(INR 2.0-3.0)
Stroke or systemic
embolism
1.27% 1.60%
Major bleeding 2.13% 3.09%
Net clinical outcomes* 6.13% 7.20%
* stroke, systemic embolism, major bleeding, or death from any cause
In the study Safety and Efficacy of Oral Direct Factor Xa Inhibitor Apixaban in Japanese 
Patients with Non-Valvular Atrial Fibrillation the primary clinical endpoint was major and clinically 
relevant non-major (CRNM) bleeding, were compared with patients given apixaban 2.5mg or 5mg BID
and the warfarin (adjusted to an INR 2.0-3.0) group. Due to the small  number of patients in each group
no formal statistical testing was conducted and P-values were not calculated for this study. Major and 
CRNM bleeding events occurred in 1.4% of apixaban 2.5mg BID group (1 out of 72 patients), 1.4% of 
apixaban 5mg BID group (1 out of 71 patients) and  5.3% (4 out of 75) in the warfarin group. In both 
apixaban groups there was no incidence of stroke, systemic embolism, MI or death from any cause 
while in the warfarin group 4.1% (3 patients), had stroke events including: 1 subarachnoid hemorrhage 
and 2 ischemic strokes. No deaths occurred in the warfarin group. When evaluating the treatment effect
of apixaban 2.5mg or 5mg versus warfarin the RRR was 73.5%, ARR was 3.9%, NNT was 26.
In the study Apixaban in Patients with Atrial Fibrillation the primary outcome, occurrence of 
stroke or systemic embolism, was compared between patients given apixaban 5mg and patients given 
aspirin doses in the range of 81mg-324mg. These patients where all determined to be unsuitable for 
warfarin treatment and thus aspirin was used in the control group. Rates of stroke or systemic 
embolism were decreased in the apixaban group compared to the aspirin group (Hazard ratio 0.45; 95%
CI 0.32-0.62; P<0.001). The yearly event rates of the primary outcomes are significantly increased in 
the aspirin group (event rate of 3.7% per year) compared to the apixaban group (event rate of 1.6% per 
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year). Incidence of major bleeding was similar between both apixaban and aspirin groups (Hazard ratio 
with apixaban 1.13; 95% CI 0.74 to 1.75; P=0.57). The yearly event ratio of major bleeding for the 
apixaban group was 1.4% and 1.2% for the aspirin group. In addition the yearly death rate was 3.5% 
per year in the apixaban group and 4.4% in the aspirin group. When evaluating the treatment effect of 
apixaban 5mg versus aspirin 81-324mg the RRR was 22.7%, ARR was 0.5%, NNT was 200. Due to the
treatment benefit in favor apixaban for the primary outcome which exceeded 4 SD this study was 
terminated early. 1. Study termination was recommended after the first confirmatory data analysis. 
Table 3: Rates of Primary and Secondary Event Outcomes 
Event Rates (%) Apixaban (5mg)  Aspirin (81mg-324mg)
Stroke or systemic embolism 1.60% 3.70%
Major bleeding 1.40% 1.20%
Deaths (from any cause) 3.50% 4.40%
DISCUSSION
Anticoagulation therapy with warfarin is the gold standard therapy for patients with atrial 
fibrillation, but not only apixaban, but rivaroxaban (another Factor XA inhibitor) and dabigatran (an 
oral direct thrombin inhibitor) have also been proven to be noninferior or superior to warfarin in 
regards to stroke prevention5. A major complication of warfarin is an increased risk of intracranial 
bleeding including hemorrhagic stroke. Patients on warfarin are required to their INRs monitored to 
track their rate of anticoagulation to prevent  aforementioned bleeding.  In addition patients using 
warfarin must control their diet for foods that are high in vitamin K ( liver, green tea, green leafy 
vegetables) which is the antidote to the anticoagulative effects of the medication 5. Apixaban, unlike 
warfarin, has no required coagulation monitoring nor does the patient have to alter their diet to prevent 
interactions with the medication. A possible limitation of the studies that included warfarin are due to 
he studies not being completely blinded. Although randomization occurred blind, those patients on 
warfarin were required to have INR monitoring.
Apixaban's original indication was prevention of venous thrombosis after hip and knee surgery 
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and was recently approved by the FDA for the of stroke prevention in patients with atrial fibrillation in 
Dec 2012. Due to how recent FDA approval was to the time that the research for this study was 
conducted statistically reliable cost effective studies for apixaban when compared to warfarin are not 
available. The price of apixaban is partially covered by Medicare Part D but the out-of-pocket prices of 
the medication vary across insurance providers.
CONCLUSION
Based on the three studies above, it can be concluded that Apixaban is effective in the 
prevention of stroke in patients with non-valvular atrial fibrillation. Apixaban doses 2.5and 5mg had 
consistently lower rates of stroke, systemic embolism, and bleeding (major or CRNM) when compared 
to the groups treated with warfarin 2,3. Apixaban 5mg was proven to have lower rates of stroke or 
systemic embolism in patients which Vitamin K antagonist therapy was unsuitable, when compared to 
aspirin 81-324mg. In addition patients with atrial fibrillation, apixaban was superior to both warfarin 
(adjusted to an INR 2.0-3.0) and aspirin (81-324mg) in the indication of prevention of stroke or 
systemic embolism.
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